Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 965-969, 2022.
Article
Dans Chinois
| WPRIM
| ID: wpr-939717
ABSTRACT
Zanubrutinib is a highly selective second-generation BTK inhibitor developed in China and first approved by the U.S. Food and Drug Administration (FDA) as a novel antineoplastic drug. In recent years, with the birth of molecularly targeted drugs, the treatment of B-cell lymphoma have entered the era of targeted therapy, and immunotherapy has been widely accepted. Especially in some relapsed and refractory lymphomas, zanubrutinib has shown deep and sustained remissions and a favorable safety, which lays a foundation for precision therapy. In this review the clinical application and new progress for zanubrutinib in B-cell lymphoma was summarized briefly.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pipéridines
/
Pyrazoles
/
Pyrimidines
/
Lymphome B
/
Inhibiteurs de protéines kinases
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Journal of Experimental Hematology
Année:
2022
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS